

12-22-03

1645

Express Mailing Label No.: EV 312717176 US
Date of Deposit: December 18, 2003

Attorney Docket No. 18217-515



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chaplin, et al.

SERIAL NUMBER: 10/602,325

EXAMINER : Not Yet Assigned

FILING DATE: June 23, 2003

ART UNIT : 1645

FOR: CONTROL OF ACUTE HYPERTENSION AND CARDIOTOXICITY
IN PATIENTS TREATED WITH VASCULAR TARGETING AGENTS

Mail Stop IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References B1; C1-4; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 18217-515. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Janine M. Susan, Reg. No. 46,119

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND
POPEO, P.C.

One Financial Center

Boston, MA 02111


Telephone: (617) 542-6000

Date: December 18, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chaplin, et al.
SERIAL NUMBER: 10/602,325
FILING DATE: June 23, 2003
FOR: CONTROL OF ACUTE HYPERTENSION AND CARDIOTOXICITY
IN PATIENTS TREATED WITH VASCULAR TARGETING AGENTS

EXAMINER : Not Yet Assigned
ART UNIT : 1645



Mail Stop IDS

Commissioner for Patents

P.O. Box 1450


Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are enclosed.

The documents are being submitted before the receipt of a first Office Action on the merits. Accordingly, no fee or certification is believed due. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 18217-515.

Respectfully submitted,


Igor R. Elrifi, Reg. No. 39,529

Janine M. Susan, Reg. No. 46,119

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, MA 02111


Telephone: (617) 542-6000

Date: December 18, 2003

Express Mail Lab I No.: EV 312717176
Date of Deposit: December 18, 2003

Page 1 of 1
Attorney Docket No.: 18217-515

Please type a plus sign (+) in this box



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/602,325
	Filing Date of U.S. Nat'l Appl.	June 23, 2003
	First Named Inventor	Chaplin
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	18217-515

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 01/74360	ASTRAZENECA AB	10/11/01	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Dowlati, et al., "A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer", <i>Cancer Res.</i> , 62:3408-3416 (2002)
	C2	Honess, et al., "Comparison of Strategies to Overcome the Hypertensive Effect of Combretastatin-A-4 Phosphate in a Rat Model", <i>British J. Cancer</i> , 86(Suppl. 1):S118-S119 (2002)
	C3	Prise, et al., "The Vascular Response of Tumor and Normal Tissues in the Rat to the Vascular Targeting Agent, Combretastatin A-4-Phosphate, at Clinically Relevant Doses", <i>Int'l J. Oncology</i> , 21:717-726 (2002).
	C4	Tozer, et al., "Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues", <i>Cancer Res.</i> , 59:1626-1634 (1999).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.